Please try another search
For the nine months ended 30 September 2019, Celgene Corporation revenues increased 15% to $12.95B. Net income before extraordinary items increased 60% to $4.81B. Revenues reflect Foreign exchange contracts increase from -$24M to $65M. Net income benefited from Research and development -Other decrease of 22% to $3.16B (expense), Stock-based Compensation in R&D decrease of 32% to $326M (expense).
Period Ending: | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 |
---|---|---|---|---|
Total Revenue | 4520 | 4400 | 4025 | 4037 |
Gross Profit | 4353 | 4249 | 3885 | 3868 |
Operating Income | 2264 | 2111 | 1710 | 1807 |
Net Income | 1691 | 1571 | 1545 | 1073 |
Period Ending: | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 |
---|---|---|---|---|
Total Assets | 41363 | 39183 | 37639 | 35480 |
Total Liabilities | 29276 | 29132 | 29474 | 29319 |
Total Equity | 12087 | 10051 | 8165 | 6161 |
Period Ending: | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 |
---|---|---|---|---|
Period Length: | 9 Months | 6 Months | 3 Months | 0 Months |
Cash From Operating Activities | 5815 | 3643 | 1476 | 5171 |
Cash From Investing Activities | -201 | -338 | -295 | -6418 |
Cash From Financing Activities | -219 | -321 | 26 | -1540 |
Net Change in Cash | 5370 | 2980 | 1199 | -2779 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review